503543-43-9

Upstream product

• 33985-40-9 (3aR,4S,6R,6aR)-tetrahydro-6-methoxy-2,2-dimethylfuro-[3,4-d][1,3]dioxole-4-carbaldehyde 
• 77-76-9 2,2-dimethoxy-propane 
• 4099-85-8 ((3aR,4R,6R,6aR)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methanol 
• 327614-68-6 6-O-dimethoxytrityl-4-C-hydroxymethyl-1-O-methyl-2,3-O-isopropylidene-β-D-ribofuranose 
• 327614-69-7 5-O-benzoyl-4-C-hydroxymethyl-2,3-O-isopropylidene-1-O-methyl-β-D-ribofuranose 
• 55797-67-6 ((3aS,6R,6aR)-6-methoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxole-4,4-diyl)dimethanol 

Downstream Products

• 327614-70-0 1-O-acetyl-2,3,5-tri-O-benzoyl-4-C-methyl-β-D-ribofuranose 
• 385435-80-3 2,3,5-tri-O-benzoyl-1-O-methyl-4-C-methyl-β-D-ribofuranose 

Relevant academic research and scientific papers

MODIFIED 2' AND 3'-NUCLEOSIDE PRODRUGS FOR TREATING FLAVIVIRIDAE VIRUS INFECTIONS

PROBLEM TO BE SOLVED: To provide 2' and/or 3' prodrugs of 1', 2', 3', or 4'-branched nucleosides for treating flaviviridae virus infections. SOLUTION: The invention relates to a compound represented by formula (I) or a pharmaceutically acceptable salt of the compound. The compound is used for preventing or treating Flaviviridae virus infection and other associated conditions by administering independently, or in combination or alternation with an antiviral drug, such as interferon. [R1-R3 are H or the like; X1 and X2 are H or an alkyl group or the like; Y1 and Y3 are an alkyl group or the like.] COPYRIGHT: (C)2016,JPOandINPIT

Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside

A method and composition for treating a host infected with flavivirus or pestivirus comprising administering an effective flavivirus or pestivirus treatment amount of a described 4′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.

Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides

A compound, method and composition for treating a host infected with a hepatitis C viral comprising administering an effective hepatitis C treatment amount of a described 4′-disubstituted nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.

Synthesis and cytotoxicity of 4′-C- and 5′-C-substituted toyocamycins

Toyocamycin and some analogues have shown potent antitumor activities; however, none of them could be used clinically primarily owing to their cytotoxicity to normal human cells. In order to overcome the weakness of these nucleoside analogues, substitution of a variety of modified sugars for the ribofuranose was explored in our laboratories with expectation that certain sugar-modified toyocamycin analogues may be selectively cytotoxic to cancer cells. In this article, we report synthesis and cytotoxicity of 4′-C- and 5′-C-substituted toyocamycins, which were prepared via the condensations of 4-C- and 5-C-substituted ribofuranose derivatives 11, 12, 13, 20, 21, and 26 with the silylated form of 4-amino-6-bromo-5-cyanopyrrolo[2,3-d]pyrimidine (27) and subsequent debromination and debenzoylation. When compared to the parent toyocamycin, all these analogues showed much lower cytotoxicity to human prostate cancer cells (HTB-81), mouse melanoma cancer cells (B16) as well as normal human fibroblasts. Compound 1e showed a significant cytotoxicity to the prostate cancer cells and a moderate selectivity. The results suggested that sugar modifications, especially those that may affect phosphorylation of nucleosides, could alter cytotoxicity profile significantly.